Expenses for Jakaviwill decrease from KRW 6 million to KRW 170 thousand due to the National Health Insurance benefit

Last year, the Novartis’s marrow fibrosis treatment Jakavi, which has finally succeeded to get the National Health Insurance Benefitafter its third try, will be providedto patients with KRW 170 thousand per a monthfrom March.

On 26^th, the Health Insurance Review & Assessment Service has made an official announcement for the revision of the ‘Details on Applicable Standards and Measures for Medi...